Literature DB >> 7930726

Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children.

R G Bredius1, B H Derkx, C A Fijen, T P de Wit, M de Haas, R S Weening, J G van de Winkel, T A Out.   

Abstract

Antibodies are essential in host defense against Neisseria meningitidis. Therefore, interactions among IgG and Fc receptors (Fc gamma R) on phagocytes may be crucial. Genetic polymorphic forms of Fc gamma RIIa (CD32) express different functional activities. In a retrospective study, Fc gamma R polymorphisms were determined in 25 children who survived fulminant meningococcal septic shock: 11 had Fc gamma RIIa-R/R131, the poor IgG2-binding allotype, which is a significantly more frequent rate than found in a healthy white population (44% vs. 23%; P = .028; odds ratio = 2.67; 95% confidence interval, 1.09-6.53). The relevance of this finding was further supported by the fact that neutrophils with the Fc gamma RIIa-R/R131 allotype phagocytized N. meningitidis opsonized with polyclonal IgG2 antibodies less effectively than did IIa-H/H131 neutrophils. Our findings suggest an important role for anti-N. meningitidis IgG2 and the Fc gamma RIIa polymorphism in host defense against systemic meningococcal infections.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7930726     DOI: 10.1093/infdis/170.4.848

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

1.  Augmentation of pulmonary host defense against Pseudomonas by FcgammaRIIA cDNA transfer to the respiratory epithelium.

Authors:  S Worgall; P Bezdicek; M K Kim; J G Park; R Singh; M Christofidou-Solomidou; A Prince; I Kovesdi; A D Schreiber; R G Crystal
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

2.  Immunogenetic risk factors for anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis.

Authors:  M Gencik; S Borgmann; R Zahn; E Albert; T Sitter; J T Epplen; H Fricke
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 3.  Functions of the Fc receptors for immunoglobulin G.

Authors:  B K Flesch; J Neppert
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

4.  Opsonophagocytosis of fluorescent polystyrene beads coupled to Neisseria meningitidis serogroup A, C, Y, or W135 polysaccharide correlates with serum bactericidal activity.

Authors:  Joseph Martinez; Tamara Pilishvili; Suzanne Barnard; Joseph Caba; Willie Spear; Sandra Romero-Steiner; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

5.  Fcgamma receptor polymorphisms in populations in Ethiopia and Norway.

Authors:  L Van Den Berg; K M Myhr; B Kluge; C A Vedeler
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

6.  Serum IgG2 concentration is associated with Gm-allotypes of IgG2 but not with the R131H polymorphism of human Fc-gamma receptor type IIa.

Authors:  Heikki Sarvas; Paula Vesterinen; Olli Mäkelä
Journal:  J Clin Immunol       Date:  2002-03       Impact factor: 8.317

Review 7.  Diversity and duplicity: human FCgamma receptors in host defense and autoimmunity.

Authors:  Robert P Kimberly; Jianming Wu; Andrew W Gibson; Kaihong Su; Hongwe Qin; Xiaoli Li; Jeffrey C Edberg
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

8.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 9.  Neutrophil disorders and their management.

Authors:  R Lakshman; A Finn
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

10.  A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.

Authors:  J Wu; J C Edberg; P B Redecha; V Bansal; P M Guyre; K Coleman; J E Salmon; R P Kimberly
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.